Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver MRI could spot dangerous drug interactions early

NCT ID NCT07541807

Knowledge-focused Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether a special MRI scan can measure how two common drugs, metformin and ciclosporin, affect the liver. Twelve healthy volunteers received the MRI dye gadoxetate before and after taking the drugs. The goal was to see if the scan could detect changes in liver function, which could help identify risky drug interactions earlier in development.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gadoxetate (MRI dye), metformin, ciclosporin
What this could lead to
If successful, this could lead to a safer, non-invasive way to test how new drugs interact with the liver, reducing drug development failures.
What could go wrong
This is a very small, early-phase study in healthy volunteers, not patients. The MRI method may not prove reliable enough for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

12 people

The number who actually took part.

Started

Dec 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy volunteers responding to a call for study participation (online advertisements).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Able to provide informed consent * Age above 18 years * Able to attend for all scheduled visits * Able to adhere to instructions on pre-scan food and drinks intake * Able to lie flat for the duration of the scan Exclusion criteria Standard MRI exclusions, including: * No history of liver or kidney disease * No history of heart failure * No history of uncontrolled hypertension * No history of malignancy or premalignant conditions, past or present * No current uncontrolled infections * Not currently pregnant * Not currently breastfeeding * No regular prescribed medication, except the oral contraceptive pill * Cochlear implant * Aneurysm clips * Neurological stimulator * Implanted cardiac devices (ICD, PPM, loop recorders, or any others) * Metal heart valve * History of retained metal foreign bodies * Other implanted metal device which prevents MR imaging * Claustrophobia * Weight exceeding 140 kg * History or allergic reaction to MRI contrast agent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver dysfunction

Contacts and locations

Locations

  • Royal Hallamshire Hospital

    Sheffield, United Kingdom

  • University of Sheffield, POLARIS, 18 Claremont Crescent

    Sheffield, S10 2RX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.